Two-part Pharmacokinetic and Pharmacodynamic Study of LAS190792 in Patients With Asthma and COPD

NCT02059434 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

55

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Obstructive Pulmonary Disease (COPD)
Asthma

Interventions

DRUG: LAS190792 Dose 1
DRUG: LAS190792 Dose 2
DRUG: LAS190792 Dose 3
DRUG: LAS190792 Dose 4
DRUG: LAS190792 Dose 5
DRUG: LAS190792 Dose 6
DRUG: LAS190792 Dose 1 (Part 2)
DRUG: LAS190792 Dose 2 (Part 2)
DRUG: Tiotropium 18 μg
DRUG: Indacaterol 150 μg
DRUG: Placebo

Sponsor

AstraZeneca